Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017

  • ID: 4311816
  • Report
  • 95 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Astellas Pharma Inc
  • Clevexel Pharma SAS
  • F. Hoffmann-La Roche Ltd
  • Japan Tobacco Inc
  • MORE
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary:

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3, 12 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Diffuse Large B-Cell Lymphoma, Inflammation, Vitiligo, Allergic Conjunctivitis, Androgenic Alopecia, Asthma, Auto Inflammatory Disease, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Respiratory Tract Inflammatory Disorders, Sarcopenia, Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia.

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Astellas Pharma Inc
  • Clevexel Pharma SAS
  • F. Hoffmann-La Roche Ltd
  • Japan Tobacco Inc
  • MORE
  1. Introduction
  2. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
  3. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  13. Aclaris Therapeutics Inc
  14. Advinus Therapeutics Ltd
  15. Arrien Pharmaceuticals LLC
  16. Astellas Pharma Inc
  17. Bristol-Myers Squibb Company
  18. Chipscreen Biosciences Ltd
  19. Clevexel Pharma SAS
  20. F. Hoffmann-La Roche Ltd
  21. Japan Tobacco Inc
  22. Merck & Co Inc
  23. MYOS RENS Technology Inc
  24. Pfizer Inc
  25. Portola Pharmaceuticals Inc
  26. Simcere Pharmaceutical Group
  27. Theravance Biopharma Inc
  28. Vectura Group Plc
  29. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
  30. ARN-4079 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. ATI-50001 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. ATI-50002 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. ATI-50003 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. cerdulatinib - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. CS-510 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. CS-944X - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. CVXL-0074 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. JTE-052 - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. OST-122 - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. peficitinib hydrobromide - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. PF-06651600 - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. PNQ-401 - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile
  87. Product Description
  88. Mechanism Of Action
  89. R&D Progress
  90. Small Molecules to Inhibit JAK3 for Autoimmune Diseases and Inflammation - Drug Profile
  91. Product Description
  92. Mechanism Of Action
  93. R&D Progress
  94. Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
  95. Product Description
  96. Mechanism Of Action
  97. R&D Progress
  98. Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
  99. Product Description
  100. Mechanism Of Action
  101. R&D Progress
  102. Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
  103. Product Description
  104. Mechanism Of Action
  105. R&D Progress
  106. Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile
  107. Product Description
  108. Mechanism Of Action
  109. R&D Progress
  110. SNA-125 - Drug Profile
  111. Product Description
  112. Mechanism Of Action
  113. R&D Progress
  114. TD-1473 - Drug Profile
  115. Product Description
  116. Mechanism Of Action
  117. R&D Progress
  118. TD-3504 - Drug Profile
  119. Product Description
  120. Mechanism Of Action
  121. R&D Progress
  122. tofacitinib citrate - Drug Profile
  123. Product Description
  124. Mechanism Of Action
  125. R&D Progress
  126. VR-588 - Drug Profile
  127. Product Description
  128. Mechanism Of Action
  129. R&D Progress
  130. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  131. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
  132. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
  133. Featured News & Press Releases
  134. May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
  135. May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
  136. May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
  137. May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis
  138. May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine
  139. Mar 27, 2017: XELJANZ Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis
  140. Mar 15, 2017: Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
  141. Mar 13, 2017: European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA
  142. Mar 04, 2017: Pfizer to Present Psoriatic Arthritis Data at American Academy of Dermatology Annual Meeting
  143. Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  144. Feb 16, 2017: Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ (tofacitinib citrate) Compared to Humira (adalimumab)
  145. Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  146. Jan 27, 2017: Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
  147. Dec 07, 2016: Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
  148. Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
  149. Appendix
  150. Methodology
  151. Coverage
  152. Secondary Research
  153. Primary Research
  154. Expert Panel Validation
  155. Contact Us
  156. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Companies, H1
  6. Products under Development by Companies, H1
  7. Products under Development by Companies, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1 2017 (Contd..2), H1
  9. Products under Development by Companies, H1 2017 (Contd..3), H1
  10. Number of Products by Stage and Mechanism of Actions, H1
  11. Number of Products by Stage and Route of Administration, H1
  12. Number of Products by Stage and Molecule Type, H1
  13. Pipeline by Aclaris Therapeutics Inc, H1
  14. Pipeline by Advinus Therapeutics Ltd, H1
  15. Pipeline by Arrien Pharmaceuticals LLC, H1
  16. Pipeline by Astellas Pharma Inc, H1
  17. Pipeline by Bristol-Myers Squibb Company, H1
  18. Pipeline by Chipscreen Biosciences Ltd, H1
  19. Pipeline by Clevexel Pharma SAS, H1
  20. Pipeline by F. Hoffmann-La Roche Ltd, H1
  21. Pipeline by Japan Tobacco Inc, H1
  22. Pipeline by Merck & Co Inc, H1
  23. Pipeline by MYOS RENS Technology Inc, H1
  24. Pipeline by Pfizer Inc, H1
  25. Pipeline by Portola Pharmaceuticals Inc, H1
  26. Pipeline by Simcere Pharmaceutical Group, H1
  27. Pipeline by Theravance Biopharma Inc, H1
  28. Pipeline by Vectura Group Plc, H1
  29. Dormant Products, H1
  30. Dormant Products, H1 2017 (Contd..1), H1
  31. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aclaris Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Chipscreen Biosciences Ltd
  • Clevexel Pharma SAS
  • F. Hoffmann-La Roche Ltd
  • Japan Tobacco Inc
  • Merck & Co Inc
  • MYOS RENS Technology Inc
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Vectura Group Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll